Journal of Gandhara Medical and Dental Sciences (Apr 2023)
Effect of Empagliflozin On Liver Enzymes of Patients In Non-Alcoholic Steatohepatitis In Type 2 Diabetes Mellitus
Abstract
OBJECTIVES To assess the effect of 10 mg and 25 mg once daily Empagliflozin on liver enzymes of patients of non-alcoholic steatohepatitis in patients of type 2 diabetes mellitus (T2DM). METHODOLOGY The study design was Quasi Experimental. Thirty three adult patients of Type 2 diabetes mellitus (T2DM) who were already on 2000 mg of Metformin and 100 mg of Sitagliptin and were having suboptimal glycemic control (HBA1C > 7% 0.05) decrease mean ALT levels in Group A pre-treatment and 12 weeks post-treatment. Similarly, there was a statistically significant (p > 0.05) decrease mean ALT levels in Group B pre-treatment and 12 weeks post-treatment. CONCLUSION Empagliflozin in both 10mg and 25 mg once daily doses cause statistically significant reduction in ALT levels in patients with NASH associated with T2DM
Keywords